Global Health Solutions, INC

Turn Therapeutics Inc. provided an investor presentation detailing advancements in its GX-03 drug candidate for inflammatory diseases, including upcoming clinical trial milestones and market potential.

Turn Therapeutics announced an updated Stage 2 design for its Phase 2 program of GX-03 in atopic dermatitis, incorporating interim analysis data to broaden patient evaluation across all disease severities.

Turn Therapeutics presented updated investor information highlighting positive interim results for its GX-03 drug candidate in treating moderate-to-severe Atopic Dermatitis and advancing its Onychomycosis program.

Turn Therapeutics announced positive interim findings from its Phase 2 GX-03 trial for atopic dermatitis, showing high efficacy and a favorable safety profile, leading to trial optimization.

Turn Therapeutics announced a peer-reviewed publication in the Journal of Dermatological Treatment detailing the efficacy of GX-03 in a murine dermatitis model.

Turn Therapeutics announced its CEO will present at the Jefferies Global Healthcare Conference on June 4, 2026, providing an update on its clinical-stage biotechnology.

Turn Therapeutics reports a net loss of $0.97 million for Q1 2026, with cash reserves projected to last into Q1 2027, alongside securing a $25 million debt facility.

Turn Therapeutics Inc. completed its Nasdaq direct listing and secured significant financing, but reported increased net losses and faces going concern doubts.

Turn Therapeutics' 2025 annual report details progress in its lead eczema drug program and new partnerships, alongside significant net losses and a going concern warning.

Director Martin William Dewhurst was granted 71,666 stock options in Turn Therapeutics Inc. as part of the company's 2025 Omnibus Incentive Plan.

Turn Therapeutics Inc. director Andrew Gengos was granted 95,000 stock options with an exercise price of $5.75.

Director Arthur F. Golden was granted 89,584 stock options in Turn Therapeutics Inc. as part of the company's incentive plan.

Director Kent Edward Kester was granted 83,334 stock options in Turn Therapeutics Inc. as part of the company's 2025 Omnibus Incentive Plan.

Turn Therapeutics CEO Bradley Burnam transferred 600,000 shares of common stock to family trusts via gift transactions.

Bradley Evan Burnam, CEO of Turn Therapeutics Inc., has acquired 300,000 shares of common stock, increasing his beneficial ownership.

Turn Therapeutics, a biopharmaceutical company, reported significant losses and expressed substantial doubt about its ability to continue as a going concern, despite advancing multiple drug and medical device candidates.

Turn Therapeutics, a biopharmaceutical company, plans a direct listing on Nasdaq for the resale of up to 17.87 million shares, despite significant net losses and a 'going concern' warning.

Turn Therapeutics, a biopharmaceutical company focused on dermatology and vaccine delivery, is preparing for a direct listing on Nasdaq, aiming to fund its advanced clinical trials and expand its proprietary PermaFusion technology.

Turn Therapeutics Inc., a pharmaceutical and medical device development company, files an S-1 registration statement for a direct listing on Nasdaq, focusing on its proprietary PermaFusion platform for dermatology and vaccine programs.

Bradley Burnam has filed a Schedule 13G reporting beneficial ownership of 15,716,260 shares of Turn Therapeutics Inc. common stock.